Comparative Pharmacology
Head-to-head clinical analysis: HYDRODIURIL versus MICROZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDRODIURIL versus MICROZIDE.
HYDRODIURIL vs MICROZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits sodium-chloride symporter in the distal convoluted tubule of the kidney, increasing excretion of sodium and water, reducing plasma volume and cardiac output.
Inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the nephron, reducing reabsorption of sodium and chloride, leading to increased excretion of water and electrolytes, and a decrease in blood volume and peripheral vascular resistance.
25-100 mg orally once daily. For hypertension: 12.5-25 mg once daily.
12.5-25 mg orally once daily for hypertension; 25-100 mg orally once daily for edema.
None Documented
None Documented
Terminal elimination half-life is approximately 5.6–14.8 hours (mean ~10 hours); clinically, duration of diuresis correlates with half-life, allowing once or twice daily dosing.
Terminal elimination half-life: 8-12 hours (prolonged in renal impairment; up to 30 hours in severe insufficiency).
Renal: approximately 95% eliminated unchanged in urine via glomerular filtration and tubular secretion; biliary/fecal: <5%.
Primarily renal (approximately 70% unchanged drug; remainder as metabolites and conjugates); minimal biliary/fecal (<10%).
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic